• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Stage appropriate therapy for COPD].

作者信息

Hamm H

机构信息

Akutkrankenhaus u. Rehabilitationsklinik für Atemwegs-und Tumorerkrankungen, Asklepios Nordseeklinik, Westerland/Sylt.

出版信息

Internist (Berl). 2006 Sep;47(9):901-2, 904-7. doi: 10.1007/s00108-006-1701-0.

DOI:10.1007/s00108-006-1701-0
PMID:16900364
Abstract

The treatment of chronic obstructive pulmonary disease (COPD) has improved substantially over recent years, and is increasingly based on evidence from prospective studies. Cessation of smoking is the most important and effective single measure which can be taken. In the early stages, intensive measures for nicotine withdrawal should be taken to prevent the catastrophic effects of disease progression. Pharmacological treatment of COPD in the earlier stages (0-II) should be symptom oriented. Asymptomatic patients at these stages do not require permanent pharmacotherapy. From Stage II, COPD patients benefit from pulmonary rehabilitation programs. Patients with stages III and IV should usually be put on long-term corticosteroid inhalation, preferably in combination with long-acting bronchodilators. Systemic corticosteroids, even at low doses, are not indicated. They are useful only for the short-term treatment of acute exacerbations. These treatment modalities improve the quality of life and morbidity of COPD patients. They also decrease exacerbations and hospitalization rates, which should help to reduce mortality due to this important disease.

摘要

相似文献

1
[Stage appropriate therapy for COPD].
Internist (Berl). 2006 Sep;47(9):901-2, 904-7. doi: 10.1007/s00108-006-1701-0.
2
Common lung conditions: chronic obstructive pulmonary disease.常见肺部疾病:慢性阻塞性肺疾病
FP Essent. 2013 Jun;409:23-31.
3
[Long-term treatment strategy in chronic obstructive pulmonary disease: how to change the course of the disease].[慢性阻塞性肺疾病的长期治疗策略:如何改变疾病进程]
Presse Med. 2014 Dec;43(12 Pt 1):1368-80. doi: 10.1016/j.lpm.2014.09.009. Epub 2014 Nov 1.
4
Optimizing treatment of chronic obstructive pulmonary disease: an assessment of current therapies.优化慢性阻塞性肺疾病的治疗:当前疗法评估
Am J Med. 2007 Aug;120(8 Suppl 1):S4-13. doi: 10.1016/j.amjmed.2007.04.007.
5
[Chronic obstructive pulmonary disease (COPD): diagnosis and treatment].[慢性阻塞性肺疾病(COPD):诊断与治疗]
Dtsch Med Wochenschr. 2004 Mar 5;129(10):490-3. doi: 10.1055/s-2004-820537.
6
Contemporary management of chronic obstructive pulmonary disease: scientific review.慢性阻塞性肺疾病的当代管理:科学综述
JAMA. 2003 Nov 5;290(17):2301-12. doi: 10.1001/jama.290.17.2301.
7
Chronic obstructive pulmonary disease--a treatable disease.慢性阻塞性肺疾病——可治疗的疾病。
Swiss Med Wkly. 2013 Apr 11;143:w13777. doi: 10.4414/smw.2013.13777. eCollection 2013.
8
Chronic obstructive pulmonary disease.
Clin Evid. 2002 Jun(7):1344-57.
9
[Not Available].[无可用内容]
Praxis (Bern 1994). 2017 Apr;106(9):465-469. doi: 10.1024/1661-8157/a002659.
10
[COPD routine management in France: are guidelines used in clinical practice?].[法国慢性阻塞性肺疾病的常规管理:临床实践中是否遵循指南?]
Rev Mal Respir. 2010;27(1):11-8. doi: 10.1016/j.rmr.2009.08.002. Epub 2009 Dec 30.

本文引用的文献

1
American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation.美国胸科学会/欧洲呼吸学会关于肺康复的声明。
Am J Respir Crit Care Med. 2006 Jun 15;173(12):1390-413. doi: 10.1164/rccm.200508-1211ST.
2
Glucocorticoid pathways in chronic obstructive pulmonary disease therapy.慢性阻塞性肺疾病治疗中的糖皮质激素途径。
Proc Am Thorac Soc. 2005;2(4):313-9; discussion 340-1. doi: 10.1513/pats.200504-035SR.
3
Chronic obstructive pulmonary disease outcome measurements: what's important? What's useful?
慢性阻塞性肺疾病的结局测量:什么是重要的?什么是有用的?
Proc Am Thorac Soc. 2005;2(4):267-71; discussion 290-1. doi: 10.1513/pats.200504-036SR.
4
Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease.吸入性糖皮质激素与慢性阻塞性肺疾病的死亡率
Thorax. 2005 Dec;60(12):992-7. doi: 10.1136/thx.2005.045385. Epub 2005 Oct 14.
5
Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.噻托溴铵(一种每日一次吸入用抗胆碱能支气管扩张剂)预防慢性阻塞性肺疾病急性加重的随机试验。
Ann Intern Med. 2005 Sep 6;143(5):317-26. doi: 10.7326/0003-4819-143-5-200509060-00007.
6
Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial.罗氟司特——一种用于慢性阻塞性肺疾病的口服抗炎治疗药物:一项随机对照试验。
Lancet. 2005;366(9485):563-71. doi: 10.1016/S0140-6736(05)67100-0.
7
Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.噻托溴铵每日一次、福莫特罗每日两次以及两者联合每日一次用于慢性阻塞性肺疾病患者的比较。
Eur Respir J. 2005 Aug;26(2):214-22. doi: 10.1183/09031936.05.00140404.
8
Bronchodilator response in the lung health study over 11 yrs.11年肺部健康研究中的支气管扩张剂反应
Eur Respir J. 2005 Jul;26(1):45-51. doi: 10.1183/09031936.05.00102604.
9
COPD: current therapeutic interventions and future approaches.慢性阻塞性肺疾病:当前的治疗干预措施及未来方法
Eur Respir J. 2005 Jun;25(6):1084-106. doi: 10.1183/09031936.05.00139104.
10
Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.N-乙酰半胱氨酸对慢性阻塞性肺疾病预后的影响(N-乙酰半胱氨酸成本-效用研究中的支气管炎随机试验,BRONCUS):一项随机安慰剂对照试验
Lancet. 2005;365(9470):1552-60. doi: 10.1016/S0140-6736(05)66456-2.